<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02196116</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2013/02</org_study_id>
    <nct_id>NCT02196116</nct_id>
  </id_info>
  <brief_title>Amyloïd Load in Elderly Population: Effect of Cognitive Reserve</brief_title>
  <acronym>EDUMA</acronym>
  <official_title>Amyloïd Load in Elderly Population: Effect of Cognitive Reserve</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fondation Plan Alzheimer</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>General Electric Healthcare</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research aim to explore relationships between the presence of amyloid burden and
      cognitive performance, and its modulation by educational level. For this purpose we will
      combine Positron emission tomography (PET) imaging and neuropsychological assessment acquired
      on 3 groups of subjects, from two population-based cohorts &quot;3C&quot; and &quot;AMIMage&quot; The first group
      includes cognitively intact participants who will serve as controls, the second group,
      subjects with mild cognitive impairments without memory complaint and the third, subjects
      with both mild cognitive impairments and memory complaint.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Influence of educational level on the relationship between disease-specific lesion
      development and cognitive function will be assessed, as measured by amyloid PET imaging and a
      battery of neuropsychological tests at the very early stages of the disease, comparatively to
      age-matched controls. In addition, this project will explore the influence of cognitive
      complaint.

      It's assumed that 1) the amyloid-PET measures in age-matched controls and subjects from the
      two cohorts will correlate with cognitive performances; 2) the amyloid burden will be higher
      in high- than in low-educated subjects with similar cognitive impairment; and 3) similarly
      the amyloid burden will be higher in subjects with cognitive complaint compared to subjects
      without cognitive complaint.

      Considering a longer term, the clinical follow-up of study participants will allow to
      investigate the prognosis value of amyloid load for improving the prediction of cognitive
      decline and disease progression.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Amyloid load</measure>
    <time_frame>at inclusion (day 0)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neuropsychological scores</measure>
    <time_frame>At inclusion (Day 0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Educational level</measure>
    <time_frame>At inclusion (Day 0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Memory complaint</measure>
    <time_frame>At inclusion (Day 0)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Plaque, Amyloid</condition>
  <condition>Cognitive Deficits</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Controls</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cognitively-impaired subjects without dementia and without memory</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cognitively-impaired subjects without dementia and with memory</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PET</intervention_name>
    <description>PET Scan with [18F]-Flutemetamol</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MRI</intervention_name>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>neuropsychological tests</intervention_name>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Participation in the AMI or 3C cohorts Group 1- Controls

          -  MMSE &gt; 24 or &gt; 26 for low and high levels of education, respectively.

          -  Without memory impairment (for episodic memory) on the Free and Cued Selective
             Reminding Test RL/RI-16 items (FCSRT), free recall &gt; 22 and total recall &gt;42,
             according to the thresholds for population-based studies

          -  Without memory complaint

          -  Without dementia Group 2- Cognitively-impaired subjects without dementia and without
             memory complaints

          -  Mini Mental State Evaluation (MMSE) &lt; 24 or &lt; 26 for low and high levels of education,
             respectively

          -  With memory impairments according to the RL/RI-16 test (free recall≤22 and/or total
             recall ≤42), according to the thresholds for population-based studies defined by
             Auriacombe et al., 2010.

          -  Without memory complaint

          -  Without dementia Group 3- Cognitively-impaired subjects without dementia and with
             memory complaints

          -  MMSE &lt; 24 or &lt; 26 for low and high levels of education, respectively

          -  With memory impairments according to the RL/RI-16 test (same thresholds as above)

          -  With memory complaint

          -  Without dementia

        Exclusion Criteria:

          -  Being left handed

          -  Presence of dementia (based on the clinical diagnosis)

          -  Presence of stroke

          -  Presence of Parkinson's disease

          -  Presence of a counter-indication for MRI

          -  Presence of a counter-indication for PET Scan with [18F]-Flutemetamol

          -  Presence of any health problem preventing travel to the imaging service of the
             University Hospital

          -  Being under the legal guardianship of another person or being unable to provide
             consent to participate

          -  Pregnant or breastfeeding woman
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michèle ALLARD, MD-PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michèle ALLARD, MD-PhD</last_name>
    <email>Michele.allard@chu-bordeaux.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Caroline BUISSON, CRA</last_name>
    <email>caroline.buisson@chu-bordeaux.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele ALLARD, MD</last_name>
      <email>michele.allard@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Michèle ALLARD, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-François DARTIGUES, Md, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe FERNANDEZ, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Simon ARNOULD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Henri De CLERMONT GALLERANDE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paolo ZANOTTI FREGONARA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Igor SIBON, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexandra FOUBERT, Md</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 17, 2014</study_first_submitted>
  <study_first_submitted_qc>July 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2014</study_first_posted>
  <last_update_submitted>February 11, 2015</last_update_submitted>
  <last_update_submitted_qc>February 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer disease</keyword>
  <keyword>amyloid load</keyword>
  <keyword>educational level</keyword>
  <keyword>cognitive performances</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amyloidosis</mesh_term>
    <mesh_term>Cognition Disorders</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
    <mesh_term>Plaque, Amyloid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

